ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "79ea5c99-eb35-4f62-acb3-3afb776c3783"}, "_deposit": {"id": "17395", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "17395"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00017395", "sets": ["1563"]}, "item_9_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2014-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1-2", "bibliographicPageEnd": "9", "bibliographicPageStart": "1", "bibliographicVolumeNumber": "76", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science"}]}]}, "item_9_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Carboplatin is a platinum-based anticancer drug that has been long used to treat many types of solid cancer. Because the clearance of carboplatin strongly correlates with the glomerular filtration rate (GFR), its dosage is calculated with the Calvert formula on the basis of the patient’s GFR to achieve the target area under the plasma drug concentration-time curve (AUC) for each patient. However, many lines of evidence from previous clinical studies should be interpreted with caution because different methods were used to estimate drug clearance and derive the dosage of carboplatin. There is a particularly high risk of carboplatin overdosing when the dosage is determined on the basis of standardized serum creatinine values. When deciding the dose of carboplatin for adult Japanese patients, preferred methods to assess renal function instead of directly measuring GFR include (1) 24-h urinary collection-based creatinine clearance adjusted by adding 0.2 mg/dl to the serum creatinine concentration measured by standardized methods, and (2) equation-based GFR (eGFR) with a back calculation to units of ml/min per subject. Given the limitations of serum creatinine-based GFR estimations, the GFR or creatinine clearance should be directly measured in each patient whenever possible. To ensure patient safety and facilitate a medical-team approach, the single most appropriate method available at each institute or medical team should be consistently used to calculate the dose of carboplatin with the Calvert formula.", "subitem_description_type": "Abstract"}]}, "item_9_identifier_60": {"attribute_name": "URI", "attribute_value_mlt": [{"subitem_identifier_type": "URI", "subitem_identifier_uri": "http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/7612/7612.html"}, {"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/2237/19478"}]}, "item_9_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.76.1-2.1", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University School of Medicine"}]}, "item_9_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_9_source_id_7": {"attribute_name": "ISSN(print)", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "ANDO, YUICHI"}], "nameIdentifiers": [{"nameIdentifier": "51082", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "SHIMOKATA, TOMOYA"}], "nameIdentifiers": [{"nameIdentifier": "51083", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "YASUDA, YOSHINARI"}], "nameIdentifiers": [{"nameIdentifier": "51084", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "HASEGAWA, YOSHINORI"}], "nameIdentifiers": [{"nameIdentifier": "51085", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-02-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "01_Ando.pdf", "filesize": [{"value": "198.5 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 198500.0, "url": {"label": "01_Ando.pdf", "url": "https://nagoya.repo.nii.ac.jp/record/17395/files/01_Ando.pdf"}, "version_id": "67c7b2bf-9fb5-4847-bdc3-1d46dd274784"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "carboplatin", "subitem_subject_scheme": "Other"}, {"subitem_subject": "pharmacokinetics", "subitem_subject_scheme": "Other"}, {"subitem_subject": "creatinine clearance", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Carboplatin Dosing for Adult Japanese Patients", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Carboplatin Dosing for Adult Japanese Patients"}]}, "item_type_id": "9", "owner": "1", "path": ["1563"], "permalink_uri": "https://doi.org/10.18999/nagjms.76.1-2.1", "pubdate": {"attribute_name": "公開日", "attribute_value": "2014-03-03"}, "publish_date": "2014-03-03", "publish_status": "0", "recid": "17395", "relation": {}, "relation_version_is_last": true, "title": ["Carboplatin Dosing for Adult Japanese Patients"], "weko_shared_id": null}
  1. C100 医学部/医学系研究科
  2. C100b 紀要
  3. Nagoya journal of medical science
  4. 76(1-2)

Carboplatin Dosing for Adult Japanese Patients

https://doi.org/10.18999/nagjms.76.1-2.1
https://doi.org/10.18999/nagjms.76.1-2.1
bfc30ac2-3bf7-4b72-9f24-24625227dfea
名前 / ファイル ライセンス アクション
01_Ando.pdf 01_Ando.pdf (198.5 kB)
Item type 紀要論文 / Departmental Bulletin Paper(1)
公開日 2014-03-03
タイトル
タイトル Carboplatin Dosing for Adult Japanese Patients
著者 ANDO, YUICHI

× ANDO, YUICHI

WEKO 51082

ANDO, YUICHI

Search repository
SHIMOKATA, TOMOYA

× SHIMOKATA, TOMOYA

WEKO 51083

SHIMOKATA, TOMOYA

Search repository
YASUDA, YOSHINARI

× YASUDA, YOSHINARI

WEKO 51084

YASUDA, YOSHINARI

Search repository
HASEGAWA, YOSHINORI

× HASEGAWA, YOSHINORI

WEKO 51085

HASEGAWA, YOSHINORI

Search repository
キーワード
主題Scheme Other
主題 carboplatin
キーワード
主題Scheme Other
主題 pharmacokinetics
キーワード
主題Scheme Other
主題 creatinine clearance
抄録
内容記述 Carboplatin is a platinum-based anticancer drug that has been long used to treat many types of solid cancer. Because the clearance of carboplatin strongly correlates with the glomerular filtration rate (GFR), its dosage is calculated with the Calvert formula on the basis of the patient’s GFR to achieve the target area under the plasma drug concentration-time curve (AUC) for each patient. However, many lines of evidence from previous clinical studies should be interpreted with caution because different methods were used to estimate drug clearance and derive the dosage of carboplatin. There is a particularly high risk of carboplatin overdosing when the dosage is determined on the basis of standardized serum creatinine values. When deciding the dose of carboplatin for adult Japanese patients, preferred methods to assess renal function instead of directly measuring GFR include (1) 24-h urinary collection-based creatinine clearance adjusted by adding 0.2 mg/dl to the serum creatinine concentration measured by standardized methods, and (2) equation-based GFR (eGFR) with a back calculation to units of ml/min per subject. Given the limitations of serum creatinine-based GFR estimations, the GFR or creatinine clearance should be directly measured in each patient whenever possible. To ensure patient safety and facilitate a medical-team approach, the single most appropriate method available at each institute or medical team should be consistently used to calculate the dose of carboplatin with the Calvert formula.
内容記述タイプ Abstract
出版者
出版者 Nagoya University School of Medicine
言語
言語 eng
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
ID登録
ID登録 10.18999/nagjms.76.1-2.1
ID登録タイプ JaLC
ISSN(print)
収録物識別子タイプ ISSN
収録物識別子 0027-7622
書誌情報 Nagoya Journal of Medical Science

巻 76, 号 1-2, p. 1-9, 発行日 2014-02
著者版フラグ
値 publisher
URI
識別子 http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/7612/7612.html
識別子タイプ URI
URI
識別子 http://hdl.handle.net/2237/19478
識別子タイプ HDL
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 17:09:40.708378
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3